Identification
Name Sevelamer
Accession Number DB00658 (APRD01226)
Type small molecule
Description Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. When taken with meals, sevelamer binds to dietary phosphate and prevents its absorption. It is marketed by Genzyme under the trade name Renagel.
Structure
Categories (*)
Molecular Weight 149.619
Groups approved
Monoisotopic Weight 149.060741718
Pharmacology
Indication For the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on hemodialysis.
Mechanism of action Sevelamer prevents hyperphosphatemia by binding to dietary phosphate in the gut, preventing its absorption and thus decreasing serum parathyroid hormone levels.
Absorption Not absorbed following oral administration, however no absorption studies have been performed in patients with renal disease.
Protein binding Not Available
Biotransformation Not Available
Route of elimination Not Available
Toxicity Sevelamer has been given to normal healthy volunteers in doses of up to 14 grams per day for eight days with no adverse effects. Sevelamer has been given in average doses up to 13 grams per day to hemodialysis patients. There are no reported overdosages of sevelamer in patients. Since sevelamer is not absorbed, the risk of systemic toxicity is low.
Affected organisms
  • Humans and other mammals
Interactions
Drug Interactions
Drug Mechanism of interaction
Ciprofloxacin Sevelamer decreases ciprofloxacin bioavailability
Cyclosporine Sevelamer decreases the effect of cyclosporine
Trovafloxacin Sevelamer may decrease the absorption of orally administered Trovafloxacin. The Sevelamer formulation contains iron that may intefere with Trovafloxacin absorption. Administer Trovafloxacin 2 hours before or 6 hours after the Sevelamer dose to minimize the interaction.
Food Interactions Not Available
Phosphate
Name Phosphate
Gene Name Not Available
Pharmacological action yes
Actions binder
References
  • Cannata-Andia JB, Rodriguez-Garcia M, Roman-Garcia P, Tunon-le Poultel D, Lopez-Hernandez F, Rodriguez-Puyol D: New therapies: calcimimetics, phosphate binders and vitamin D receptor activators. Pediatr Nephrol. 2010 Apr;25(4):609-16. Epub 2010 Feb 12. - Pubmed
  • Novak JE, Szczech LA: Phosphate binders in chronic kidney disease and end-stage renal disease: a patient-centered approach. Semin Dial. 2009 Jan-Feb;22(1):56-63. Epub 2008 Oct 16. - Pubmed
  • Salusky IB: A new era in phosphate binder therapy: what are the options? Kidney Int Suppl. 2006 Dec;(105):S10-5. - Pubmed
  • Schucker JJ, Ward KE: Hyperphosphatemia and phosphate binders. Am J Health Syst Pharm. 2005 Nov 15;62(22):2355-61. - Pubmed
DTHybrid score Not Available